INSTRUCTIONS STIs: Options & considerations
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/nm.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 34. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $21.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results. There is no minimum passing grade.
* Registration deadline is October 31, 2014.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by LWW together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other health care facilities on nursingcenter.com. Call 1–800–787–8985 for details.
Lippincott Williams & Wilkins, publisher of Nursing Management, will award 2.0 contact hours for this continuing nursing education activity.
LWW is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.0 contact hours, the District of Columbia, and Florida #FBN2454. Your certificate is valid in all states.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers to its continuing nursing education activities only and does not imply Commission on Accreditation approval or endorsement of any commercial product.
STIs: Options & considerations
GENERAL PURPOSE: To provide an overview of CDC guidelines for screening, treatment, and strategies for counseling about STIs. LEARNING OBJECTIVES: After reading this article and taking the test, you should be able to: 1. Describe risk factors, testing, and assessment of STIs. 2. Illustrate the guidelines and other considerations for treating STIs.
1. Factors associated with the disproportionate prevalence of STIs include all except
a. the stigma of diagnosis.
b. religious beliefs.
c. barriers to healthcare resources.
d. ethnic minority status.
2. Which is a psychosocial or situational factor that influences sexual behavior?
a. history of abuse
b. type and frequency of sexual encounters
c. substance use
d. use of contraceptives
3. Which of the following isn't one of the five P's used in assessment for STIs?
a. Ask about partner(s).
b. Ask about pregnancy prevention.
c. Ask about prior medical history.
d. Ask about STI protection.
4. To rule out infection in the patient reporting multiple risk behaviors, test for
a. the suspected organism only.
b. the organism most commonly found in that age group.
c. an inexpensive panel of common causative organisms.
d. the fullest suspected range of infection.
5. An STI screening is recommended for all patients reporting
a. sexual monogamy.
b. a history of blood transfusion.
c. termination of a relationship.
d. inconsistent use of condoms.
6. The clinician should routinely screen for STI/HIV when initiating treatment for
a. pelvic inflammatory disease.
c. hepatitis A.
7. Patients using I.drugs should be tested for HIV at least every
b. 6 months.
d. 2 to 3 years.
8. Clinical manifestations of chlamydia may present as
a. vaginal itching.
b. fever and lymphadenopathy.
c. mucopurulent discharge in women.
d. genital rash in men.
9. Which drug may be used to treat chlamydia?
10. After treatment for chlamydia, patients should be retested in
a. 1 week.
b. 2 weeks.
c. 3 months.
d. 6 months.
11. Disseminated gonococcal infection presents as
a. fever, malaise, lymphadenopathy, and skin rash.
b. genital warts.
c. mucopurulent discharge and dysuria.
d. diffuse skin lesions, arthralgia, arthritis, or tenosynovitis.
12. When initiating treatment for gonorrhea, clinicians should be aware that
a. coinfection with HIV is uncommon.
b. women should have a urethral swab tested.
c. complications may cause pneumonitis or central nervous system involvement.
d. testing for chlamydia, syphilis, and HIV is also indicated.
13. Treatment for gonorrhea includes a single dose of
14. Clinical manifestations of acute retroviral syndrome may include fever, malaise,
a. lymphadenopathy, and skin rash.
b. mucopurulent discharge, and bleeding.
c. and genital warts.
d. and precancerous lesions on the pharynx.
15. HPV may present as
a. dysuria and discharge in men.
b. fever, malaise, and lymphadenopathy.
c. skin rash.
d. genital warts or precancerous lesions on the cervix.
16. Treatment of HPV may include
17. Cardiac or gummatous lesions are symptomatic of a/an
a. diffuse trichomoniasis infection.
b. tertiary syphilis infection.
c. tertiary gonococcal infection.
d. HIV infection.
18. Which statement about expedited partner therapy is accurate?
a. It requires treating the partner within 7 days of diagnosis.
b. Therapy may be delivered to the partner by the patient.
c. It's indicated when the partner is likely to self-initiate evaluation and therapy.
d. Effectiveness of this approach has been demonstrated for treating chlamydia in same gender relationships in men.